SAVED
File name
.JPG
File alt. text
Image should be
px wide x
px tall.
Select Image
Select Image
L
O
G
I
N
EXISTING USERS
NEW USERS
password:
Forgotten your password?
password:
LOG IN
REGISTER
The Gastroenterology Training Handbook
For Specialist Registrars
HOME
OESOPHAGUS
•Gastro Oesophageal Reflux Disease
•Oesophageal Cancer
•Oesophageal Dysmotility
•Benign Oesophageal Lesions
•Miscellaneous
•Dysphagia
STOMACH
•Obesity Surgery
•Clinical Presentations of Gastric Conditions
•Gastric Cancer
•Gastric Polyps and Masses
•Peptic Ulcer Disease
•Gastritis and Gastropathy
•Miscellaneous
SMALL BOWEL
•Coeliac Disease
•Small Bowel Infections
•Small Bowel Masses
•Miscellaneous
COLON
•Colorectal and Anal Cancer
•Diagnostic Pathways for Colonic Disease
•Colonic Vascular Disorders
•Anal Diseases
•Various Colitides
•Colonic Motility Disorders
•Miscellaneous
•Colonic Infection
LIVER
•Alcohol
•Liver Failure
•Miscellaneous
•Ascites
•Bilirubin Metabolism
•Vascular Problems
•Clinical Presentations
•Liver Masses
•Hepatitis B
•Hepatitis C
•Autoimmune Conditions
•Metabolic Conditions
•Treatments
•Various Viruses
•Hepatopulmonary Disorders
•Liver Imaging
BILIARY
•Gallstone Disease
•Biliary Cancers
•Biliary Parasites
•Miscellaneous
NUTRITION
•Nutrition Therapy
•Minerals
•Proteins, Fats and Sugars
•Vitamins
•Clinical Conditions and Nutrition
PANCREAS
•Pancreatitis
•Pancreatic Masses and Cysts
•Pancreatic Cancers
•Other
IBD
•Epidemiology
•IBD Diagnosis
•Extra Intestinal Manifestations
•Surgery
•Treatment
MISCELLANEOUS
•Bleeding
•Rheumatological Disease
•Infection
•Vascular Lesions
•Other
home -
Liver -
Bilirubin Metabolism -
Crigler Najjar Syndrome
search
Ask a question in the forum
Written by Dr Sebastian Zeki
MCQs for this page
Crigler Najjar Syndrome
View large version
Embed image
paste this code into your webpage / blog to share.
Written by Dr Sebastian Zeki
Dec. absorption of bilirubin/ production of
bilirubin or inc. clearance
Hepatocyte transplantation
Diagnosis —
Treatment —
Distinction of type 1 from type
II disease.
Type 1 is assoc. with lower [serum
bilirubin] -values can overlap with
type I, especially with underlying
haemolysis.
Phenobarbital can reduce type II; not
type I.
No conjugated bilirubin in type 1.
DNA extracted from any tissue can
make the diagnosis.
Gene therapy —
By introduction of a normal bilirubin-UGT gene
(UGT1A1).
Ex vivo gene transduction —
Harvest hepatocytes from patient,
culture and insert normal gene. Difficult
Vector-mediated gene delivery.
------Adenoviral vectors —
Locate to liver, transfer trangene to
non-dividing cells. But need repeated injections which induce
immune response.
------SV40 and lentiviruses —
Less immunogenicity appears to be
negligible, dont localise to liver unless given via portal vein
Receptor-mediated gene delivery to the liver —
Using carrier
proteins- short lived
Site-directed gene conversion —
By aligning specific sequences
with a mismatch so host gene repair mechanism used.
Calcium phosphate supplementation —
Traps unconjugated bilirubin in gut, lowers
the [bilirubin] by 20-50 %.
Orlistat —
Captures intestinal unconjugated
bilirubin.
Inhibition of bilirubin production —H
eme
oxygenase, eg tin-protoporphyrin or
tin-mesoporphyrin, inhibits enzyme- better
in neonates than adults in which the effect is
short lived.
Plasmapheresis —
Most efficient way to deal with a crisis
Liver transplantation
This has resulted in long-term
survival and is the only curative
therapy.
Phototherapy
—
Most patients treated
with this can survive past
puberty, but get
kernicterus later.
No treatment: Most dead in 18m
With treatment
25% brain damage
Isolated unconjugated hyper
-
bilirubin few days after birth
Type 1 Disease
This is due to mutations in
UGT1A1 gene.
Because Gilbert’s is so common,
patients can have Gilbert’s with
Crigler- Najaar which can lead to
severe hyperbilirubinemia, since
the activity of the normal allele is
reduced to about 30 % of normal.
Gilbert’s with Crigler-Najaar
explains the frequent finding of
intermediate levels of hyperbili
-
rubinemia in the family members
of patients with Crigler-Najjar
syndrome, both types I and II.
Type 2 Disease
This is less marked (serum bilirubin <20
mg/dL).
50% are icteric at <1 year.
Bilirubin ranges from 8-18 mg/dL.
UGT defect is much less severe than in
type I disease (residual bilirubin-UGT
activity of 2-8 % vs up to 38%).
The enzyme is catalytically effective only if
hyperbilirubinemia is present (low affinity).
Only 50 % of bilirubin is conjugated and
excreted into bile.
Conjugate is mainly bilirubin monoglucu
-
roniderather than
diglucuronide.
The molecular defect
is in one of 5 exons
coding bilirubin-UGT.
Unconjugated hyperbilirubinemia is < 20
mg/dL but can rise to 40 mg/dL if fasting/
intercurrent illness.
Other LFT’s normal.
Only treat high bilirubin if affects QOL -less
likely to get neuro problems.
Treat with phenobarbital or clofibrate
which reduces serum bilirubin levels by
>25 %.
Patients respond in 2-3 weeks.
Crigler-Najjar syndrome
Related Stories
•
•
•
•
•